Furthermore, AMP-dNM treatment was shown to reduce the development of atherosclerosis in APOE*3-Leiden and low-density lipoprotein receptor -/- mice by lowering plasma cholesterol levels [62]. Here, VLDLR is linked to atherosclerosis.